Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NiTi Challenges Surgical Staple Market

This article was originally published in Start Up

Executive Summary

Surgical staples underpin surgeries in every operating room in the country, and are, well, staples of the businesses of Ethicon Endo-Surgery and Covidien, which together control 95% of the US surgical staples market. But now, in colorectal, bariatric, and thoracic procedures, some of the most promising markets for surgical staples, a threat is entering from the wings. NiTi Surgical Solutions has begun selling an alternative to staples, with a platform that it calls BioDynamix Anastomosis Technology, by which it describes compression devices that adjust to an organ's diameter to promote healing that's as natural as possible.

You may also be interested in...



Covidien Set to Compete in Vascular Business

Covidien, following the acquisition of Vnus Medical Technologies and Bacchus Vascular, is establishing a global business unit focused on vascular surgery.

Shionogi's Oral COVID Drug Set For Global Access Through MPP

Agreement with UN-affiliated body set to expand global availability in lower income countries of Japanese firm’s protease inhibitor, which has faced approval road bumps at home but now looks set to move forward on positive new Phase III data.

Medicare CED Update Targets Study ‘Efficiency,’ But May Not Ease Data Collection Burden

It's not clear that the proposed revisions and additions to the Centers for Medicare and Medicaid Services’ existing coverage with evidence development study design requirements would address what some experts view as a program failure – the fact that sponsors of the vast majority of technologies subject to CED have not generated the data CMS is looking for. 

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

MT037624

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel